{"protocolSection":{"identificationModule":{"nctId":"NCT03131791","orgStudyIdInfo":{"id":"16MMHIS066e"},"organization":{"fullName":"Mackay Memorial Hospital","class":"OTHER"},"briefTitle":"Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity","officialTitle":"Radial Extracorporeal Shock Wave Versus Botulinum Toxin A in the Treatment of Post-Stroke Upper Limb Spasticity: A Randomized Non-Inferiority Trial"},"statusModule":{"statusVerifiedDate":"2018-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-07-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-09-30","type":"ACTUAL"},"studyFirstSubmitDate":"2017-04-21","studyFirstSubmitQcDate":"2017-04-24","studyFirstPostDateStruct":{"date":"2017-04-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-08-17","lastUpdatePostDateStruct":{"date":"2018-08-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Gwo-Chi Hu,PHD","investigatorTitle":"PHD","investigatorAffiliation":"Mackay Memorial Hospital"},"leadSponsor":{"name":"Mackay Memorial Hospital","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Botulinum toxin type A (BoNT-A) is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. However, there were no studies to compare the effect of rESWT and BoNT-A injection for treatment on spasticity.","detailedDescription":"Botulinum toxin type A (BoNT-A) is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. However, the treatments of BoNT-A injection are associated with high cost and invasive treatment. Recent studies have showed that radial extracorporeal shock wave (rESWT) is a novel, effective and safety treatment method for the spasticity. However, there were no studies to compare the effect of rESWT and BoNT-A injection for treatment on spasticity."},"conditionsModule":{"conditions":["Post-Stroke Upper Limb Spasticity"],"keywords":["Extracorporeal Shock Wave","Spasticity in stokes","Botulinum toxin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"group A : shock wave, group B: Botulinum Toxin Injection","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":42,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"shock wave","type":"EXPERIMENTAL","description":"The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.","interventionNames":["Device: Shock Wave"]},{"label":"Botulinum toxin A","type":"EXPERIMENTAL","description":"We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.","interventionNames":["Drug: Botulinum toxin A"]}],"interventions":[{"type":"DEVICE","name":"Shock Wave","description":"42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.","armGroupLabels":["shock wave"]},{"type":"DRUG","name":"Botulinum toxin A","description":"42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.","armGroupLabels":["Botulinum toxin A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The change of spasticity of elbow","description":"Modified Ashworth Scale (MAS) for spasticity","timeFrame":"Between baseline and 4 weeks post-treatment"}],"secondaryOutcomes":[{"measure":"The change of Tardieu scale scores for the elbow and wrist","description":"Tardieu scale scores for spasticity","timeFrame":"Between baseline and 1, 4,8 weeks post-treatment"},{"measure":"The change of upper limb function","description":"The Fugl-Meyer Assessment (FMA) for upper limb function","timeFrame":"Between baseline and 1,4,8 weeks post-treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged between 18-80 year-old\n2. The onset of stroke must be at least 6 months previously\n3. Spasticity measured as Modified Asthow Scale more(MAS) than 1+\n4. Signed informed consent form\n\nExclusion Criteria:\n\n1. Patients with marked contractures in the elbow and wrist (MAS\\>4)\n2. Resistant hypertension, coagulation disorders, malignant tumors, pregnancy, pacemakers, cognitive disorders\n3. Prior or planned treatment with phenol or alcohol nerve blocks, intrathecal baclofen, or BoNT-A injection within the six months preceding the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Mackay Memorial Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}}]},"referencesModule":{"references":[{"pmid":"30392753","type":"DERIVED","citation":"Wu YT, Yu HK, Chen LR, Chang CN, Chen YM, Hu GC. Extracorporeal Shock Waves Versus Botulinum Toxin Type A in the Treatment of Poststroke Upper Limb Spasticity: A Randomized Noninferiority Trial. Arch Phys Med Rehabil. 2018 Nov;99(11):2143-2150. doi: 10.1016/j.apmr.2018.05.035. Epub 2018 Jul 4."}]}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-08-30","uploadDate":"2017-08-30T23:05","filename":"Prot_SAP_000.pdf","size":178538}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M15267","name":"Shock","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Carrier","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Carrier","relevance":"HIGH"},{"id":"M250251","name":"incobotulinumtoxinA","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}